The ARHGEF5 antibody is a crucial tool for studying the ARHGEF5 protein, a member of the Rho guanine nucleotide exchange factor (RhoGEF) family. RhoGEFs regulate Rho GTPases, which are pivotal in cytoskeletal reorganization, cell migration, and signaling pathways. ARHGEF5. also known as TIM or Ephexin-2. activates RhoA and Rac1 GTPases by catalyzing the exchange of GDP for GTP. It plays roles in diverse cellular processes, including cell adhesion, polarity, and proliferation, and is implicated in cancer progression, neurological disorders, and cardiovascular diseases.
ARHGEF5 antibodies are widely used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to detect protein expression, localization, and interactions. Research has linked ARHGEF5 dysregulation to tumor invasiveness, metastasis, and drug resistance, particularly in breast, lung, and gastric cancers. Its involvement in Rho-ROCK and MAPK signaling pathways underscores its potential as a therapeutic target. Additionally, ARHGEF5 interacts with cell junction proteins, influencing epithelial-mesenchymal transition (EMT), a key mechanism in cancer metastasis.
These antibodies also aid in exploring ARHGEF5’s role in neuronal development and synaptic plasticity, as well as vascular remodeling. Studies using ARHGEF5-knockout models or siRNA/CRISPR-based approaches, combined with antibody validation, highlight its physiological and pathological significance. As a research reagent, the ARHGEF5 antibody enables both mechanistic insights into cellular dynamics and biomarker discovery for disease diagnosis or treatment monitoring. Its specificity and reliability are critical for advancing understanding of Rho GTPase-mediated signaling networks.